FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved Bayer's supplemental application for NUBEQA (darolutamide), expanding or updating its labeling related to nonmetastatic castration-resistant prosta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmetastatic Castration-resistant Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

SUPPL AP for NUBEQA (DAROLUTAMIDE)